Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

TODA PHARMA : revenue, balance sheet and financial ratios

TODA PHARMA is a French company founded 18 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques. Based in STRASBOURG (67000), this company of category PME shows in 2022 a revenue of 12.0 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - TODA PHARMA (SIREN 498776830)
Indicator 2023 2022 2021 2020 2019 2018 2017
Revenue N/C 11 985 445 € N/C N/C N/C N/C N/C
Net income 5 380 € 1 556 607 € 1 188 800 € 1 599 439 € 84 470 € 144 162 € 29 365 €
EBITDA N/C 2 178 790 € N/C N/C N/C N/C N/C
Net margin N/C 13.0% N/C N/C N/C N/C N/C

Revenue and income statement

In 2023, TODA PHARMA generates positive net income of 5 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2023: 29 k€ -> 5 k€.

Net income (2023) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

5 380 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 9%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 73%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2023) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

8.528%

Financial autonomy (2023) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

73.49%

Asset age ratio (2023) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

60.2%

Solvency indicators evolution
TODA PHARMA

Sector positioning

Debt ratio
8.53 2023
2021
2022
2023
Q1: 0.0
Med: 5.57
Q3: 50.77
Average

In 2023, the debt ratio of TODA PHARMA (8.53) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
73.49% 2023
2021
2022
2023
Q1: 13.47%
Med: 38.42%
Q3: 58.45%
Excellent +8 pts over 3 years

In 2023, the financial autonomy of TODA PHARMA (73.5%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Repayment capacity
0.25 years 2022
2022
Q1: 0.0 years
Med: 0.01 years
Q3: 1.6 years
Average

In 2022, the repayment capacity of TODA PHARMA (0.25) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 445.46. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2023) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

445.464

Liquidity indicators evolution
TODA PHARMA

Sector positioning

Liquidity ratio
445.46 2023
2021
2022
2023
Q1: 133.58
Med: 205.53
Q3: 329.15
Excellent +55 pts over 3 years

In 2023, the liquidity ratio of TODA PHARMA (445.46) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Interest coverage
6.84x 2022
2022
Q1: 0.0x
Med: 0.34x
Q3: 4.26x
Excellent

In 2022, the interest coverage of TODA PHARMA (6.8x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2023) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2023) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2023) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2023) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
TODA PHARMA

Positioning of TODA PHARMA in its sector

Comparison with sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Valuation estimate

Based on 124 transactions of similar company sales (all years), the value of TODA PHARMA is estimated at 4 419 € (range 1 682€ - 16 140€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2023
124 transactions
1k€ 4k€ 16k€
4 419 € Range: 1 682€ - 16 140€
NAF 5 all-time

Valuation method used

Net Income Multiple
5 380 € × 0.8x = 4 420 €
Range: 1 682€ - 16 140€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 124 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de gros (commerce interentreprises) de produits pharmaceutiques)

Compare TODA PHARMA with other companies in the same sector:

Frequently asked questions about TODA PHARMA

What is the revenue of TODA PHARMA ?

The revenue of TODA PHARMA in 2022 is 12.0 M€.

Is TODA PHARMA profitable?

Yes, TODA PHARMA generated a net profit of 5 k€ in 2023.

Where is the headquarters of TODA PHARMA ?

The headquarters of TODA PHARMA is located in STRASBOURG (67000), in the department Bas-Rhin.

Where to find the tax return of TODA PHARMA ?

The tax return of TODA PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does TODA PHARMA operate?

TODA PHARMA operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.